Richard J Knight1, Ana K Islam2, Christine Pham3, Edward A Graviss4, Duc T Nguyen4, Linda W Moore1, Anna Kagan5, Archana R Sadhu6, Hemangshu Podder1, A Osama Gaber1. 1. Department of Surgery, Houston Methodist Hospital, Houston, TX. 2. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX. 3. Department of Pharmacy, Houston Methodist Hospital, Houston, TX. 4. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX. 5. Houston Kidney Consultants, Houston, TX. 6. Department of Internal Medicine, Houston Methodist Hospital, Houston, TX.
Abstract
BACKGROUND: Excessive weight (EW) gain is common after solid organ transplantation, but there is little information concerning obesity after pancreas transplantation. The study goal was to characterize EW gain after kidney-pancreas (KP) transplantation. METHODS: This was a retrospective single-center review of 100 KP recipients transplanted between September 2007 and June 2015. RESULTS: The median percent weight gain for all recipients at 1 year posttransplant was 10% (interquartile range, 2.7%-19.3%) of baseline weight. EW gain, defined as greater than or equal to a 19% 1-year increase in weight, included all recipients (n = 26) above the upper limit of interquartile range for weight gain at 1 year. In multivariate analysis, recipient age <40 years, the use of tacrolimus/mammalian target of rapamycin immunosuppression, and an acute rejection event were independent risk factors for EW gain. At a mean follow-up of 43±23 months, there was no difference in patient or graft survival between the EW and non-EW cohorts. Although mean hemoglobin A1c levels between groups were equivalent, the EW versus non-EW cohort displayed a significant increase in mean insulin levels and a trend towards higher C-peptide levels. Criteria for posttransplant metabolic syndrome was met in 34.6% of EW versus 17.6% of non-EW cohorts (P = 0.07). CONCLUSIONS: At intermediate-term follow-up, EW gain after KP transplantation was not associated with an increased risk of death or graft loss, although there was a trend toward a greater risk of posttransplant metabolic syndrome. There may be a metabolic consequence of successful pancreas transplantation that results in EW gain in a proportion of recipients, leading to an increased risk of long-term cardiovascular complications.
BACKGROUND: Excessive weight (EW) gain is common after solid organ transplantation, but there is little information concerning obesity after pancreas transplantation. The study goal was to characterize EW gain after kidney-pancreas (KP) transplantation. METHODS: This was a retrospective single-center review of 100 KP recipients transplanted between September 2007 and June 2015. RESULTS: The median percent weight gain for all recipients at 1 year posttransplant was 10% (interquartile range, 2.7%-19.3%) of baseline weight. EW gain, defined as greater than or equal to a 19% 1-year increase in weight, included all recipients (n = 26) above the upper limit of interquartile range for weight gain at 1 year. In multivariate analysis, recipient age <40 years, the use of tacrolimus/mammalian target of rapamycin immunosuppression, and an acute rejection event were independent risk factors for EW gain. At a mean follow-up of 43±23 months, there was no difference in patient or graft survival between the EW and non-EW cohorts. Although mean hemoglobin A1c levels between groups were equivalent, the EW versus non-EW cohort displayed a significant increase in mean insulin levels and a trend towards higher C-peptide levels. Criteria for posttransplant metabolic syndrome was met in 34.6% of EW versus 17.6% of non-EW cohorts (P = 0.07). CONCLUSIONS: At intermediate-term follow-up, EW gain after KP transplantation was not associated with an increased risk of death or graft loss, although there was a trend toward a greater risk of posttransplant metabolic syndrome. There may be a metabolic consequence of successful pancreas transplantation that results in EW gain in a proportion of recipients, leading to an increased risk of long-term cardiovascular complications.
Authors: Jeevan Prakash Gopal; Adam McLean; Jeremy Crane; Paul Herbert; Vassilios Papalois; Frank J M F Dor; Anand Rathnasamy Muthusamy Journal: Transpl Int Date: 2022-06-15 Impact factor: 3.842
Authors: Fouad Kandeel; Mohamed El-Shahawy; Gagandeep Singh; Donald C Dafoe; Jeffrey S Isenberg; Arthur D Riggs Journal: Cell Transplant Date: 2021 Jan-Dec Impact factor: 4.064
Authors: Kurtis J Swanson; Emily Joachim; Annamalai Arunachalam; Fahad Aziz; Neetika Garg; Maha Mohamed; Arjang Djamali; Robert R Redfield; Dixon B Kaufman; Jon Odorico; Didier Mandelbrot; Sandesh Parajuli Journal: Transplant Direct Date: 2020-02-24